{"id":"W4404417044","doi":"10.3390/curroncol31110529","title":"Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110","year":2024,"lang":"en","type":"erratum","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Capecitabine; Aromatase inhibitor; Aromatase; Human Epidermal Growth Factor Receptor 2; HER2 negative; Internal medicine; Metastatic breast cancer; Hormone receptor; Oncology; Second line; Cancer research; Breast cancer; Cancer; First line","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003854992,0.002598228,0.002264844,0.002899859,0.002512137,0.004068335,0.003944106,0.008384912,0.03382676],"category_scores_gemma":[0.04670047,0.00113666,0.002269487,0.001421985,0.002005254,0.001963574,0.001744542,0.01494343,0.02482975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003922121,"about_ca_system_score_gemma":0.005128084,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01584271,"about_ca_topic_score_gemma":0.01782289,"domain_scores_codex":[0.9967746,0.0005297892,0.0005176652,0.0004158352,0.001397436,0.0003646783],"domain_scores_gemma":[0.9862003,0.003412558,0.0009680134,0.0005819033,0.007876276,0.0009609008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000210987,0.00000319759,0.00002284632,0.00007932311,0.000009344518,0.0002140031,0.00001209698,0.00001509745,0.00002035636,0.0002096227,0.9969959,0.002397133],"study_design_scores_gemma":[0.00009051501,0.00002163666,0.0004405455,0.0004528425,0.00005993287,0.0009890787,0.00004795265,0.0001343966,0.0002038529,0.0007459947,0.9967788,0.00003431897],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00006293476,0.001318795,0.0002212686,0.05823919,0.9384197,0.00001709305,0.0005147136,0.000131719,0.001074598],"genre_scores_gemma":[0.006573841,0.01426446,0.001863697,0.162543,0.7149817,0.0001896515,0.001717146,0.000681494,0.09718503],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.03382676,"threshold_uncertainty_score":0.1131618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04541429623633902,"score_gpt":0.3958328626615461,"score_spread":0.3504185664252071,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}